Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$209M in Q4 2023 → — now. Hover for any quarter.
As reported for the quarter ended June 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| N N/a | NaN% | New | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2025 · filed July 24, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bristol-myers Squibb Co | Exited | −295,000 | −$18M | — |
| Amgen Inc | Exited | −50,000 | −$15.6M | — |
| Biogen Inc | Exited | −113,500 | −$15.5M | — |
| EL Eli Lilly & Co | Exited | −18,000 | −$14.9M | — |
| Insmed Inc | Exited | −186,384 | −$14.2M | — |
| UP Ultragenyx Pharmaceutical In | Exited | −379,303 | −$13.7M | — |
| Bridgebio Pharma Inc | Exited | −390,644 | −$13.5M | — |
| Perrigo Co PLC | Exited | −479,517 | −$13.4M | — |
| Roivant Sciences Ltd | Exited | −1,300,000 | −$13.1M | — |
| TP Teva Pharmaceutical Inds Ltd | Exited | −801,806 | −$12.3M | — |
Showing the 10 largest of 22 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | Exited | −31,500 | −$22.4M | — |
| Johnson & Johnson | Exited | −141,572 | −$20.5M | — |
| Abbvie Inc | Exited | −101,996 | −$18.1M | — |
| Bristol-myers Squibb Co | New | +295,000 | +$18M | 7.8% |
| Biogen Inc | New | +113,500 | +$15.5M | 6.8% |
| Sarepta Therapeutics Inc | Exited | −124,256 | −$15.1M | — |
| EL Eli Lilly & Co | New | +18,000 | +$14.9M | 6.5% |
| Roivant Sciences Ltd | New | +1,300,000 | +$13.1M | 5.7% |
| Royalty Pharma PLC | Trimmed | −407,965 | −$12.7M | 4.8% |
| Viridian Therapeutics Inc | Exited | −628,677 | −$12.1M | — |
Showing the 10 largest of 31 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | Exited | −359,025 | −$30.1M | — |
| Bristol-myers Squibb Co | Exited | −574,057 | −$29.7M | — |
| Johnson & Johnson | New | +141,572 | +$20.5M | 8.4% |
| Abbvie Inc | New | +101,996 | +$18.1M | 7.4% |
| Agilent Technologies Inc | Exited | −120,485 | −$17.9M | — |
| Legend Biotech Corp | Exited | −325,953 | −$15.9M | — |
| EL Eli Lilly & Co | Exited | −17,299 | −$15.3M | — |
| HB Harmony Biosciences Hldgs In | Exited | −376,315 | −$15.1M | — |
| Jazz Pharmaceuticals PLC | Exited | −117,500 | −$13.1M | — |
| TP Teva Pharmaceutical Inds Ltd | New | +584,883 | +$12.9M | 5.3% |
Showing the 10 largest of 38 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bristol-myers Squibb Co | New | +574,057 | +$29.7M | 8.8% |
| Biomarin Pharmaceutical Inc | Exited | −273,533 | −$22.5M | — |
| Merck & Co Inc | Exited | −175,600 | −$21.7M | — |
| Amgen Inc | Exited | −64,201 | −$20.1M | — |
| Agilent Technologies Inc | New | +120,485 | +$17.9M | 5.3% |
| Biogen Inc | Exited | −76,726 | −$17.8M | — |
| Kenvue Inc | Exited | −960,400 | −$17.5M | — |
| EL Eli Lilly & Co | New | +17,299 | +$15.3M | 4.5% |
| Regeneron Pharmaceuticals | New | +14,476 | +$15.2M | 4.5% |
| TP Teva Pharmaceutical Inds Ltd | Exited | −911,900 | −$14.8M | — |
Showing the 10 largest of 39 changes.
quarter ended June 30, 2024 · filed August 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bristol-myers Squibb Co | Exited | −446,900 | −$24.2M | — |
| Merck & Co Inc | New | +175,600 | +$21.7M | 6.6% |
| Amgen Inc | New | +64,201 | +$20.1M | 6.1% |
| Kenvue Inc | New | +960,400 | +$17.5M | 5.3% |
| Regeneron Pharmaceuticals | Exited | −16,360 | −$15.7M | — |
| UP Ultragenyx Pharmaceutical In | New | +365,000 | +$15M | 4.5% |
| Cytokinetics Inc | New | +236,900 | +$12.8M | 3.9% |
| Acadia Pharmaceuticals Inc | Exited | −658,409 | −$12.2M | — |
| Legend Biotech Corp | Added | +263,300 | +$11.7M | 4.6% |
| Halozyme Therapeutics Inc | Exited | −255,049 | −$10.4M | — |
Showing the 10 largest of 38 changes.
quarter ended March 31, 2024 · filed May 15, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | New | +265,436 | +$19.4M | 7.5% |
| Bristol-myers Squibb Co | Added | +306,900 | +$16.6M | 9.3% |
| Amgen Inc | Exited | −57,381 | −$16.5M | — |
| Regeneron Pharmaceuticals | New | +16,360 | +$15.7M | 6.1% |
| Merck & Co Inc | Exited | −136,098 | −$14.8M | — |
| Amicus Therapeutics Inc | Exited | −947,418 | −$13.4M | — |
| Ionis Pharmaceuticals Inc | New | +289,366 | +$12.5M | 4.8% |
| Sarepta Therapeutics Inc | New | +94,379 | +$12.2M | 4.7% |
| Roivant Sciences Ltd | Exited | −1,000,000 | −$11.2M | — |
| Biogen Inc | New | +52,000 | +$11.2M | 4.3% |
Showing the 10 largest of 35 changes.
Loading...
